RPC 1063, a highly effective form of Gilenya with less serious side effects is recruiting for a larger Phase 3 trial.
The oral medicine is called RPC1063 by the company developing it, Receptos, Inc.
MS CONNECTION newsletter has an article stating that Dr. Robert Fox from Cleveland Clinic is the national principle investigator. This Phase 3 trial will recruit 1,410 people with RRMS at 28 sites nationwide.
Medpage 9/14/14 article titled: Novel MS Tx Appears Free of Cardiac Side Effectshttp://www.medpagetoday.com/MeetingC.../ECTRIMS/47647
Quotes from the article:
“BOSTON -- An investigational oral drug for multiple sclerosis (MS) with the same mechanism as the approved product fingolimod (Gilenya) was highly effective in a phase II trial with seemingly fewer side effects than the earlier drug, researchers said here.”
“Mean gadolinium-enhancing lesion counts were lowered by more than 90%”
“But perhaps most important was that the drug appeared to have almost no effect on cardiac function. Fingolimod, by contrast, slows the heart rate significantly with the first dose”
“Rates of other adverse effects potentially related to the drug were also low.”
“Fingolimod (Gilenya) is one of the most potent drugs now available for MS, but its adverse effects have been a major clinical concern and, for most clinicians, it is usually reserved for patients with inadequate responses to safer agents.
Consequently, an oral drug with similar efficacy lacking its adverse effects could easily become everyone's favorite first-line treatment for MS.” End Quotes.
This trial will be of great interest to many MSers. A highly effective oral med with a very good safety profile is quite appealing. The Phase2/3 results presented at Boston last week were excellent.
Contact info for the trial is in the MS Connection newsletter.
The oral medicine is called RPC1063 by the company developing it, Receptos, Inc.
MS CONNECTION newsletter has an article stating that Dr. Robert Fox from Cleveland Clinic is the national principle investigator. This Phase 3 trial will recruit 1,410 people with RRMS at 28 sites nationwide.
Medpage 9/14/14 article titled: Novel MS Tx Appears Free of Cardiac Side Effectshttp://www.medpagetoday.com/MeetingC.../ECTRIMS/47647
Quotes from the article:
“BOSTON -- An investigational oral drug for multiple sclerosis (MS) with the same mechanism as the approved product fingolimod (Gilenya) was highly effective in a phase II trial with seemingly fewer side effects than the earlier drug, researchers said here.”
“Mean gadolinium-enhancing lesion counts were lowered by more than 90%”
“But perhaps most important was that the drug appeared to have almost no effect on cardiac function. Fingolimod, by contrast, slows the heart rate significantly with the first dose”
“Rates of other adverse effects potentially related to the drug were also low.”
“Fingolimod (Gilenya) is one of the most potent drugs now available for MS, but its adverse effects have been a major clinical concern and, for most clinicians, it is usually reserved for patients with inadequate responses to safer agents.
Consequently, an oral drug with similar efficacy lacking its adverse effects could easily become everyone's favorite first-line treatment for MS.” End Quotes.
This trial will be of great interest to many MSers. A highly effective oral med with a very good safety profile is quite appealing. The Phase2/3 results presented at Boston last week were excellent.
Contact info for the trial is in the MS Connection newsletter.
Comment